JCEM case report links semaglutide dose escalation to postmenopausal bleeding

The wire

1. 01Authors report new-onset vaginal bleeding after escalation to 0.5 mg weekly semaglutide; hemoglobin fell from 12.9 to 10.8 g/dL and bleeding resolved within five weeks of discontinuation.
2. 02Malignancy, structural pathology and coagulopathy were excluded, and the Naranjo score of 6 rated the reaction 'probable', so clinicians should still pursue malignancy-first workup before attributing bleeding to the drug.
3. 03This is a single case with a proposed but unproven mechanism involving rapid adipose loss altering peripheral estrogen metabolism; FSH and estradiol stayed in the postmenopausal range throughout.

From the source

Postmenopausal bleeding associated with semaglutide: a diagnostic challenge

JCEM case reports · 2026 Oct · Prasad S, Parmar V, Sharma A et al.